{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Hong Kong Biotechnology news", "home_page_url": "https://sharemaestro.com/newsreel/hk/healthcare/biotechnology/", "feed_url": "https://sharemaestro.com/newsreel/hk/healthcare/biotechnology/feed.json", "description": "Latest Biotechnology company headlines from Hong Kong, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:c8c8d889e95db493d733e7aa337d7a78593791d912f2897c2602c5bc2fe43eef", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNVTk2TExHLWxuRG5hTkZFN0VnYkpWTHZzVDdRSGhZbWZfbW9iaEN1VjBPeGk4NDl5cWhicVNPelRNYjVRS1p6ZG0yS1ZWdVE2MVlKbEQ1eVFDWTdUcXZJS0FnNHJyeF8zSUp3MUdaOFA0WmljUWxzRTVucFE0R1pVS0t2dTdETDRFeVVPRk0zM3Y1MHVNbF9vN3hVb19rRXZncDBVN2JBVmhyNGFrUXRHSmJhMUxfcXlITEU5YVF5Rk1yaGctZmRB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNVTk2TExHLWxuRG5hTkZFN0VnYkpWTHZzVDdRSGhZbWZfbW9iaEN1VjBPeGk4NDl5cWhicVNPelRNYjVRS1p6ZG0yS1ZWdVE2MVlKbEQ1eVFDWTdUcXZJS0FnNHJyeF8zSUp3MUdaOFA0WmljUWxzRTVucFE0R1pVS0t2dTdETDRFeVVPRk0zM3Y1MHVNbF9vN3hVb19rRXZncDBVN2JBVmhyNGFrUXRHSmJhMUxfcXlITEU5YVF5Rk1yaGctZmRB?oc=5", "title": "Viva Biotech Sets Board Meeting to Approve Interim Results and Mull Dividend", "content_text": "Viva Biotech Sets Board Meeting to Approve Interim Results and Mull Dividend", "date_published": "2026-08-14T08:57:44+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "1873"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1873", "name": "Viva Biotech Holdings", "sentiment_url": "https://sharemaestro.com/sentiment/3323c5a5-8cfe-42f2-89b4-1624d43065fd/"}]}}, {"id": "source:00536030d7d2d4999cb9c704413e9637a9a741ede0a287ab68d1325a88651bd7", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQX3d4cUw1RWNzTEFtZVJkUnVLWi1KbVY3azZZSGlLS21saU9IcENiMDdSNDlpMVVLTWM3Z3k4OXJIM1UtcF9IUGdObmlERVM5WlVyN29PYm8yV2xCaEhHNkZQcER4RGdxNVZBcFlWamI5TjBMZ0dSd2tvRThlOE9JWnVJM19SVDg5Z0d4NVVNOGhEOGpwdWFDeU1FYnNQOW1BWUlSR3lOUlA1Snd3MGJ4aktHX081VkU4Y25aUlluZVVNdVY2TUZ1R2l1THl5dFJEMkY0?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQX3d4cUw1RWNzTEFtZVJkUnVLWi1KbVY3azZZSGlLS21saU9IcENiMDdSNDlpMVVLTWM3Z3k4OXJIM1UtcF9IUGdObmlERVM5WlVyN29PYm8yV2xCaEhHNkZQcER4RGdxNVZBcFlWamI5TjBMZ0dSd2tvRThlOE9JWnVJM19SVDg5Z0d4NVVNOGhEOGpwdWFDeU1FYnNQOW1BWUlSR3lOUlA1Snd3MGJ4aktHX081VkU4Y25aUlluZVVNdVY2TUZ1R2l1THl5dFJEMkY0?oc=5", "title": "Shanghai Bio-heart Sets Board Meeting to Review Interim Results and Possible Dividend", "content_text": "Shanghai Bio-heart Sets Board Meeting to Review Interim Results and Possible Dividend", "date_published": "2026-08-14T08:57:42+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "2185"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2185", "name": "Shanghai Bio-heart Biological Technology Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/f78539b8-87ac-49d8-bff1-ada6b1dc8daf/"}]}}, {"id": "source:e5a20bda332e7c09e4ec2358e1cb0e760e9c13215c924e78b5f7a4f6384fa775", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNLW1BQ3RDZ05XZ2VNZk5RR1pKTElETWt2Qkt1azRqZjZyd0E2S1FKb00ybDZEU1pvdmdZQVk3dVJlbzJBYlpGbFNxaWsza2FPWXJ6OWhVbzk1b192X0czcG1QTGxMQ1ZtWGJLcE5YTlJEMFFsM2o3MHMzQjk4dFJLTnZqQ1dfT0Jlb1EzY2pGZ3JnU01fT2JMUWdVeXhHemFsU1ZiWGwyblFLeWpLMFhzUDBXT3EzWklNamZiZzEyeUQ3OXNZTFNYMkJaZTdpRjU4cDBIVUZ5ZmdzdHQ4QTBkcWhfR3pmdw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNLW1BQ3RDZ05XZ2VNZk5RR1pKTElETWt2Qkt1azRqZjZyd0E2S1FKb00ybDZEU1pvdmdZQVk3dVJlbzJBYlpGbFNxaWsza2FPWXJ6OWhVbzk1b192X0czcG1QTGxMQ1ZtWGJLcE5YTlJEMFFsM2o3MHMzQjk4dFJLTnZqQ1dfT0Jlb1EzY2pGZ3JnU01fT2JMUWdVeXhHemFsU1ZiWGwyblFLeWpLMFhzUDBXT3EzWklNamZiZzEyeUQ3OXNZTFNYMkJaZTdpRjU4cDBIVUZ5ZmdzdHQ4QTBkcWhfR3pmdw?oc=5", "title": "383,728,970 H Shares of Guangzhou Innogen Pharmaceutical Group Co., Ltd are subject to a Lock-Up Agreement Ending on 14-AUG-2026.", "content_text": "383,728,970 H Shares of Guangzhou Innogen Pharmaceutical Group Co., Ltd are subject to a Lock-Up Agreement Ending on 14-AUG-2026.", "date_published": "2026-08-14T00:37:25+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Market update", "2591"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2591", "name": "Guangzhou Innogen Pharmaceutical Group Co., Ltd", "sentiment_url": "https://sharemaestro.com/sentiment/b2e7b5de-50d1-40ae-9dba-193877077f7a/"}]}}, {"id": "source:e75be98a118b6341c7be1ff2e4d5fa67a22f1fe813f701e9186e7443aaf3839d", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNLTN0RnpWb1hWemFWTGNScFVuaEtNM1hlWEhPRVRtWEZTVDJxWTZ6MDFzd2tLS1hQa2RrYlprTkkxOVRrYmZ1R0FsWlBWR3IxYnhPZU8yTzRfS0J1d29wZ0xQWTVqOVY3S2dHY1haaXcyQlBhZUZnR0dING9TZjNSdE1STEtELTItM1RFbWdkeER6dERRYjZYYXEzcm1qVjE0djFseF95UXB4bVJXcVh4SHdXdGxZTExXMk1YeC1ZTlI0MWFyWnV2dU1XXzkwVkpzYUlvYnVmRzktUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNLTN0RnpWb1hWemFWTGNScFVuaEtNM1hlWEhPRVRtWEZTVDJxWTZ6MDFzd2tLS1hQa2RrYlprTkkxOVRrYmZ1R0FsWlBWR3IxYnhPZU8yTzRfS0J1d29wZ0xQWTVqOVY3S2dHY1haaXcyQlBhZUZnR0dING9TZjNSdE1STEtELTItM1RFbWdkeER6dERRYjZYYXEzcm1qVjE0djFseF95UXB4bVJXcVh4SHdXdGxZTExXMk1YeC1ZTlI0MWFyWnV2dU1XXzkwVkpzYUlvYnVmRzktUQ?oc=5", "title": "Guangzhou Innogen Schedules Board Meeting to Review 2026 Interim Results and Dividend Plan", "content_text": "Guangzhou Innogen Schedules Board Meeting to Review 2026 Interim Results and Dividend Plan", "date_published": "2026-08-13T09:34:01+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "2591"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2591", "name": "Guangzhou Innogen Pharmaceutical Group Co., Ltd", "sentiment_url": "https://sharemaestro.com/sentiment/b2e7b5de-50d1-40ae-9dba-193877077f7a/"}]}}, {"id": "source:600ad22bd557ff450cdccc0f7657b5942d3c8ba776985e4725e313c0742a8287", "url": "https://finance.yahoo.com/healthcare/articles/beone-medicines-ltd-onc-q2-010458606.html", "external_url": "https://finance.yahoo.com/healthcare/articles/beone-medicines-ltd-onc-q2-010458606.html", "title": "BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...", "content_text": "This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% year-over-year growth. US BRUKINSA Sales: $893 million, representing 31% growth. TEVIMBRA Global Sales: $229 million, representing 18% growth versus the prior period. Amgen In-Licensed Portfolio Revenue: $157 million, growing 25% year over year. US Revenue: Approximately $899 million, growing 31% year over year. China Revenue: Approximately $500 million, growing 17% year over year. Europe Revenue: Approximately $208 million, growing 37% year over year. Rest of World Revenue: Approximately $73 million, more than doubled year over year. Gross Profit: $1.5 billion with gross margin of just under 90%. Operating Expenses: $1.2 billion, representing 13% growth. Income from Operations: $325 million. Net Income: $237 million, including an approximate $60 million impact from a tax audit settlement. Adjusted Income from Operations: $503 million, representing growth of more than 80% year over year. Adjusted Net Income: $444 million. Adjusted Diluted EPS: $3.84, compared with $2.25 a year ago. Free Cash Flow: $435 million, doubling from the prior year period. 2026 Revenue Guidance: Raised by $300 million to a range of $6.6 billion to $6.8 billion. 2026 GAAP Operating Income Guidance: Raised by $250 million to a range of $1 billion to $1.1 billion. 2026 Non-GAAP Operating Income Guidance: $1.7 billion to $1.8 billion. Warning! GuruFocus has detected 5 Warning Sign with ONC. Is ONC fairly valued? Test your thesis with our free DCF calculator. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points BeOne Medicines Ltd (NASDAQ:ONC) delivered a strong Q2 2026 with total revenues of $1.7 billion, up 30% year-over-year, and GAAP EPS of $2.05, up 144%. BRUKINSA continues to outperform, with global revenues exceeding $1.2 billion (31% growth) and the highest level of sustained new patient starts since launch. The company raised its 2026 revenue guidance by $300 million to $6.6-$6.8 billion and operating income guidance by $250 million to $1.0-$1.1 billion. The Phase 3 MANGROVE study showed BRUKINSA plus rituximab as the first chemo-free regimen for frontline mantle cell lymphoma, with a hazard ratio of 0.57 versus standard of care. The pipeline is advancing rapidly, with five solid tumor programs achieving proof of concept and moving to pivotal trials, including CDK4, B7-H4 ADC, and GPC3 x 4-1BB. Real-world data from over 10,500 Medicare patients showed BRUKINSA significantly reduced risk of death by 24% vs acalabrutinib and 36% vs ibrutinib. The company achieved FDA approval for BEQALZI, the first BCL-2 inhibitor for mantle cell lymphoma, expanding its hematology franchise. Free cash flow doubled year-over-year to $435 million, demonstrating strong cash generation and financial health. Story Continues Negative Points The CELESTIAL-301 study of zanubrutinib plus sonrotoclax did not meet the uMRD superiority endpoint versus venetoclax plus obinutuzumab, raising questions about the regimen's comparative efficacy. The company remains unblinded to the hazard ratio data from CELESTIAL-301, creating uncertainty about the PFS endpoint. Competition from fixed-duration regimens like acalabrutinib plus venetoclax (AV) is emerging, though the company downplays its near-term impact. The company faces potential biosimilar competition for XGEVA from its Amgen in-licensed portfolio, which could impact future revenue. Operating expenses are expected to grow at a similar year-over-year rate in 2027, indicating continued high investment levels that may pressure margins. The company's narrative on BRUKINSA's safety and efficacy is challenged by cross-trial comparisons, which may not fully account for differences in patient populations and stud", "date_published": "2026-08-13T01:04:58+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "6160"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "6160", "name": "BeOne Medicines AG", "sentiment_url": "https://sharemaestro.com/sentiment/14ab05a4-a757-4bae-a95d-8990f66c2cff/"}]}}, {"id": "source:2b89a6c256b10059dd50a2c3552aea4cb75cb48d535895085ee95232921aad1e", "url": "https://finance.yahoo.com/healthcare/articles/ivonescimab-combination-chemotherapy-approved-china-132200149.html", "external_url": "https://finance.yahoo.com/healthcare/articles/ivonescimab-combination-chemotherapy-approved-china-132200149.html", "title": "Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer", "content_text": "Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Statistically Significant Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in NSCLC or Any Tumor Type MIAMI, August 12, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in combination with chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). This marks the third NMPA-approved indication for an ivonescimab-containing regimen in China since the molecule's initial approval in May 2024. The latest NMPA approval is based on the positive results of the landmark HARMONi-6 trial, a single region, multi-center, Phase III study conducted in China and sponsored by Akeso, with all relevant data exclusively generated, managed, and analyzed by Akeso. HARMONi-6 evaluates ivonescimab in combination with platinum-based chemotherapy compared to tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous NSCLC irrespective of PD-L1 expression. Overall survival (OS) data from the Phase III HARMONi-6 trial were recently presented in the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. HARMONi-6 demonstrated statistically significant and clinically meaningful superiority in both progression-free survival (PFS) and OS. Ivonescimab continued to demonstrate an acceptable and manageable safety profile in the HARMONi-6 study, which was consistent with previous Phase III studies of ivonescimab plus chemotherapy. \"Today's approval in China marks another extraordinary milestone for ivonescimab and reinforces the strength of the clinical evidence generated to date. HARMONi-6 is the first known Phase III study in NSCLC \u2014 or any tumor type \u2014 to demonstrate a statistically significant and clinically meaningful overall survival benefit over an anti-PD-(L)1 antibody plus chemotherapy regimen in a head-to-head setting,\" said Bob Duggan, Chairman and Co-CEO of Summit. Story Continues \"For Summit, the HARMONi-6 results further strengthen our conviction in ivonescimab's potential to advance beyond today's immunotherapy standards and redefine what patients and physicians can expect from first-line cancer treatment,\" said Dr. Maky Zanganeh, President and Co-CEO of Summit. \"We congratulate our partner Akeso on this important approval and remain focused on accelerating the global development of ivonescimab for patients in our licensed territories.\" \"The NMPA approval of ivonescimab in China in combination with chemotherapy for first-line advanced squamous NSCLC represents a landmark achievement for patients, physicians and the field of oncology. Based on the HARMONi-6 trial, ivonescimab has now demonstrated both progression-free survival and overall survival superiority versus a PD-1 inhibitor plus chemotherapy regimen, establishing a new benchmark in one of the most widely treated settings in cancer care,\" said Dr. Michelle Xia, Chairwoman and Chief Executive Officer of Akeso. \"This third approval for an ivonescimab-containing regimen in China reflects the strength of Akeso's innovation platform, the dedication of our clinical investigators and patients, and the transformative potential of ivonescimab as a next-generation immuno-oncology therapy. Together with Summit, we are committed to bringing the full potential of ivonescimab to patients worldwide.\" In major markets globally, first-line therap", "date_published": "2026-08-12T13:22:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "9926"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "9926", "name": "Akeso, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/cfc96b07-c8a4-4446-a224-5b867f724c6a/"}]}}, {"id": "source:2e54bfbb0bdfb373193bb3d5c2a43197d2a4da131c24d9a77bff45bd6d4aeb1d", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNakVoM0tYVzBwT0JjVTBDMUVpX1ZxUmpZUjBiYkJwLTdfYkt5MW5vYmxLdkV3cHZjR3M1eE5pZUpzT0JRYkhITUsxTVJ3VHhoekd6enY2cV9QZFhWU3BZNXJKQ2NueHZmQS1QS0loSEN3MURWNzhfUkZEdVljZFVNdklZUkplS0x6TlZidVdWQlBKeGU5TEVSTmpyZDYxcC0xTmt5LUM2c1k5OEh5LW1taXNuRUVQN0t6ZFJhY2xGT1JYZmRYeTI0?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNakVoM0tYVzBwT0JjVTBDMUVpX1ZxUmpZUjBiYkJwLTdfYkt5MW5vYmxLdkV3cHZjR3M1eE5pZUpzT0JRYkhITUsxTVJ3VHhoekd6enY2cV9QZFhWU3BZNXJKQ2NueHZmQS1QS0loSEN3MURWNzhfUkZEdVljZFVNdklZUkplS0x6TlZidVdWQlBKeGU5TEVSTmpyZDYxcC0xTmt5LUM2c1k5OEh5LW1taXNuRUVQN0t6ZFJhY2xGT1JYZmRYeTI0?oc=5", "title": "Junshi Biosciences Sets August Board Meeting to Approve Interim 2026 Results", "content_text": "Junshi Biosciences Sets August Board Meeting to Approve Interim 2026 Results", "date_published": "2026-08-12T10:13:11+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "1877"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1877", "name": "Shanghai Junshi Biosciences Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/ae80fec0-b67d-47b2-9bd6-da53342c73f1/"}]}}, {"id": "source:25c6c21d925fc29deb867a45ff01a76f20251a3b9eef44c35ae8aa00f4114e45", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Ascletis Pharma (SEHK:1672) At 5x P B On Obesity Trial Momentum Looks About Right", "content_text": "Ascletis Pharma (SEHK:1672) At 5x P B On Obesity Trial Momentum Looks About Right", "date_published": "2026-08-12T07:57:18+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "1672"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1672", "name": "Ascletis Pharma Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/c3d1ab5c-d74a-49c7-a7f9-380f2167dfd4/"}]}}, {"id": "source:882798e25bef90730a68e81ca6a8e112c6c71325df036f797edabdf4d04c1039", "url": "https://finance.yahoo.com/healthcare/articles/belenos-biosciences-announces-positive-topline-151000504.html", "external_url": "https://finance.yahoo.com/healthcare/articles/belenos-biosciences-announces-positive-topline-151000504.html", "title": "Belenos Biosciences Announces Positive Topline Results from a Phase 2 Clinical Trial of BEL512 in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)", "content_text": "The study met its primary and all secondary endpoints at Week 24 Rapid onset of clinical activity was observed with significant improvements as early as Week 4 Durable clinical activity demonstrated following single-dose administration, supporting 6- month dosing for the treatment of CRSwNP '512 was well tolerated across all dosing groups '512 granted Breakthrough Therapy Designation in China for CRSwNP Belenos plans to initiate a Phase 3 study in CRSwNP in 1H 2027 SARASOTA, Fla., August 11, 2026--(BUSINESS WIRE)--Belenos Biosciences, Inc. (\"Belenos\"), a clinical-stage biotechnology company developing long-acting bispecific antibodies for chronic inflammatory diseases, today announced that '512 met its primary and all secondary endpoints in a double-blind, placebo-controlled Phase 2 clinical study in adults with inadequately controlled CRSwNP (NCT06930612). '512 is known as BEL512 ex-China and CM512 in Greater China. The study was conducted in China by Belenos' partner, Keymed Biosciences, and enrolled 120 patients with CRSwNP with a Nasal Polyp Score of \u22655, with at least 2 polyps per nostril and a Nasal Congestion Score of 2-3 at baseline. Patients were randomized to receive either 300 mg '512 every 12 weeks, 300 mg '512 every 24 weeks, 600 mg '512 every 24 weeks, or placebo via subcutaneous injection on top of daily intranasal corticosteroid treatment (mometasone furoate nasal spray [MFNS 200 \u00b5g QD]). Treatment lasted 24 weeks, followed by a 12-week safety follow-up. The primary endpoint was change from baseline at week 24 (W24) in Nasal Polyp Score (NPS). Additional endpoints evaluated throughout the study were: Nasal Congestion Score (NCS) Loss of Smell (LoS) Score Total Symptom Score (TSS) Sinus CT Lund-Mackay (LMK) score Sinonasal Outcome Test-22 (SNOT-22) The study met its primary and secondary endpoints with statistically significant improvements in the '512 treatment groups vs placebo at W24. Improvements were achieved by W4 and durable effects were observed throughout the treatment and follow-up periods. '512 was well tolerated across all dosing groups with overall treatment-emergent adverse events (TEAEs) rates similar to placebo, no severe TEAEs, no discontinuations in treatment groups, no serious adverse events (SAEs), and minimal anti-drug antibodies (ADA). Based on the results of this study, '512 was recently included by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) in its Breakthrough Therapy program for the treatment of CRSwNP. Story Continues \"These results provide important clinical validation for simultaneously targeting TSLP and IL-13 in treating CRSwNP,\" said Donnie McGrath, M.D., CEO of Belenos Biosciences. \"The magnitude, speed of onset and durability of improvement across objective measures of nasal polyp disease and the symptoms that matter most to patients, in conjunction with infrequent dosing indicate that BEL512 may offer patients an attractive treatment option. These findings further strengthen our conviction in BEL512 as a potentially best-in-class therapy across multiple respiratory and inflammatory diseases. We congratulate our partners at Keymed Biosciences on a well-executed study.\" Keymed is rapidly moving to initiate a Phase 3 study in CRSwNP in China in the near future and Belenos will be initiating a Phase 3 study ex-China in the first half of 2027. Detailed results are expected to be presented at a scientific meeting and submitted for publication in a peer-reviewed medical journal. \"Patients with CRSwNP experience a significant and profound impact on their quality of life, struggling to breathe through their nose, smell, and sleep normally. A treatment that works quickly and provides lasting benefits for many months after a single injection would substantially improve both the quality of life and treatment experience for my patients,\" said Dr. Stella Lee, M.D., Associate Professor of Otolaryngology\u2013Head and Neck Surgery at Harvard Medica", "date_published": "2026-08-11T15:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "2162"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2162", "name": "Keymed Biosciences Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d613420e-7080-43b0-b7e0-435c91da54a9/"}]}}, {"id": "source:33275f9074ac7e5748fea22e844b199e51f47f588264c883ad7264844f760a2d", "url": "https://finance.yahoo.com/markets/world-indices/articles/asian-equities-traded-us-american-144308450.html", "external_url": "https://finance.yahoo.com/markets/world-indices/articles/asian-equities-traded-us-american-144308450.html", "title": "Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading", "content_text": "Asian equities traded in the US as American depositary receipts were edging slightly lower Tuesday morning, declining 0.14% to 3,020.40 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by diagnostic imaging centers company Concord Medical Services (CCM) and Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-11T14:43:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "9688"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "9688", "name": "Zai Lab Limited", "sentiment_url": "https://sharemaestro.com/sentiment/6f0d5f29-758a-4179-96ee-db688e92bca8/"}]}}, {"id": "source:7d091992f15cfaed25a4e96c2a1d3ef98eadf42e7fa956b649c30379cee7b2a9", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNNkR0RXNoY0VjaENweF9oNXVOMTUyeW9aU2dNSEpBaFRBLWo5a1VINGRsM3FOQ3l3cnI2X25kRVZZSV9GUnFDNXE0c3IzQWQ5amk3UURveVRIRzFIYkVzWUVzQXVSRjZtZVZqVlFHbS1xc0Q0aldnYjEzREhXT1U3R3hjS2s2S2tPUVV5WUhZN0NXQmFPQXA0elRZQ0tteXE3V0FxalVVYmYxVnNYV081b2dRbW1uWUtGbWRNcjllVVBhRjI1LV9sbkRLcEtJQ0hrR2t2TTRYbXF6bVgzb2o0bFlR0gHnAUFVX3lxTE04SFhoY3FVS2p3VHpkalpLVEM5UnZqUFU2UXVFR1BOUVJaNTNuSENoak9Hd291alFsbmZFLUxYUTJCMDZtS3JpLW9tN2h2N214b1hIMGR5dlBOakktMTQ0RTVYWHRXNk5zNUFYV0x2amRSNGJKeWJoVE9hYlBpTkNxNW1iWE5ZOW96R1JTOWltRVBjYVRQLXR5bW9nU1RCaTBwMHVWLURZRWNNMzJSSy1RQ1dZUFBPa2xPdzBmY1VMY2lFVVVlLU1XUUpWaU9VRjlURl9WR1JEYmhmdUgtZnVXbWdGczN3aw?oc=5", "title": "Cutia Therapeutics (HKG:2487): Are Analysts Optimistic?", "content_text": "Cutia Therapeutics (HKG:2487): Are Analysts Optimistic?", "date_published": "2026-08-11T05:56:25+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "2487"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2487", "name": "Cutia Therapeutics", "sentiment_url": "https://sharemaestro.com/sentiment/c16d05c0-7950-490a-b83a-895e50b4f8af/"}]}}, {"id": "source:cc9a76fb5da4315fc9c49447a1fd0c7a9fa9fec1a6dc822ee382fbd0532aa3dd", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQSnJKbTJyN2JudElreHV0dnJXNmFLSU5pS08zUmw5TnVaMUdWNVVoR2RYcnRYbVAyeTJ6VWpnbWRvUnY1bnQ5MHVoclpCT2VRQjJFZFp2NDloTHpCZFRybElPVjg1b2tzaXYyT0VEd0JHOWJIYVRIVS1TSmdETXRNaEFqdlo2R1hpRTVhc3I3ZDhuMHRiMjhJRmpZeS16c1ZiR2EtSG9xQWtiYXZXcEdYYkdR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQSnJKbTJyN2JudElreHV0dnJXNmFLSU5pS08zUmw5TnVaMUdWNVVoR2RYcnRYbVAyeTJ6VWpnbWRvUnY1bnQ5MHVoclpCT2VRQjJFZFp2NDloTHpCZFRybElPVjg1b2tzaXYyT0VEd0JHOWJIYVRIVS1TSmdETXRNaEFqdlo2R1hpRTVhc3I3ZDhuMHRiMjhJRmpZeS16c1ZiR2EtSG9xQWtiYXZXcEdYYkdR?oc=5", "title": "Antengene Sets Board Meeting to Approve 2026 Interim Results", "content_text": "Antengene Sets Board Meeting to Approve 2026 Interim Results", "date_published": "2026-08-10T23:10:35+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "6996"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "6996", "name": "Antengene Corporation Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3a953705-10d5-42ca-92f3-2c3c0dcfa50a/"}]}}, {"id": "source:cd955509205a2e67580935731e7df2fd3863c15869e88be6bf32f1b5f88a760f", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOamw4RHE0bWhiWWZxd3M1elMwR0JhRUROWXlDLUFQRVd3U3pzdUJreHp3TlBGelA5Q2FTUFMxSGhOdjZuRjZpdE96allVSGlFQXo1Sm1sWkQ1SUlrallqZTF6YUNLWVhoZ3RJOGFNSGpXOUN0a19uaEx3ZjJwWlRrSUgwSGRPSDBBWU9QRTMzS0F0V25rbGxmblF4SmdoYVUtZ0hCMGpsMDE1R29LSWxOUzZkeV9aLXA3Mm9YYjU1QmZTOUU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOamw4RHE0bWhiWWZxd3M1elMwR0JhRUROWXlDLUFQRVd3U3pzdUJreHp3TlBGelA5Q2FTUFMxSGhOdjZuRjZpdE96allVSGlFQXo1Sm1sWkQ1SUlrallqZTF6YUNLWVhoZ3RJOGFNSGpXOUN0a19uaEx3ZjJwWlRrSUgwSGRPSDBBWU9QRTMzS0F0V25rbGxmblF4SmdoYVUtZ0hCMGpsMDE1R29LSWxOUzZkeV9aLXA3Mm9YYjU1QmZTOUU?oc=5", "title": "Junshi Biosciences Discloses Reduction in Major Shareholder\u2019s Equity Stake", "content_text": "Junshi Biosciences Discloses Reduction in Major Shareholder\u2019s Equity Stake", "date_published": "2026-08-10T13:43:36+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Deals and strategy", "1877"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1877", "name": "Shanghai Junshi Biosciences Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/ae80fec0-b67d-47b2-9bd6-da53342c73f1/"}]}}, {"id": "source:648442fce7889ee0acebc3d80ff8efe6df78d8f8f5952a614fd4df1eb0f9c48e", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNMW4tT0c2SzhzVGhRd09ZaWk5dzRZbnRpdzlRVENyWEk3M1YzV3h1azhQSWFYTGI3cDJzWm9nVS1EcU5zVXBENlViOVBjQXQ1cW5BZWEweGd6a2VBZjFtdXdsSnNtd3lQMmE5cEljTG5kWXNNNVpWbXV2bENHY3dUQXdwQ1N5TXJtRWd1ZVRVVUZULXpWZ3FjSmRNYnlfVDhqSS1lWnNlOUNSdHBHZFg1cXRZYjJEbGhTREJmeW9DM2pjMTFIRUVtNWFB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNMW4tT0c2SzhzVGhRd09ZaWk5dzRZbnRpdzlRVENyWEk3M1YzV3h1azhQSWFYTGI3cDJzWm9nVS1EcU5zVXBENlViOVBjQXQ1cW5BZWEweGd6a2VBZjFtdXdsSnNtd3lQMmE5cEljTG5kWXNNNVpWbXV2bENHY3dUQXdwQ1N5TXJtRWd1ZVRVVUZULXpWZ3FjSmRNYnlfVDhqSS1lWnNlOUNSdHBHZFg1cXRZYjJEbGhTREJmeW9DM2pjMTFIRUVtNWFB?oc=5", "title": "Shanghai Junshi Biosciences Reports Completion of Shareholder\u2019s Stake Reduction", "content_text": "Shanghai Junshi Biosciences Reports Completion of Shareholder\u2019s Stake Reduction", "date_published": "2026-08-10T13:26:05+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Deals and strategy", "1877"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1877", "name": "Shanghai Junshi Biosciences Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/ae80fec0-b67d-47b2-9bd6-da53342c73f1/"}]}}, {"id": "source:974d1dc6f545da2cc23c633adb0eac1750e682c1f04173c2d38de171cedd2144", "url": "https://finance.yahoo.com/healthcare/articles/akeso-advances-io2-0-adc2-040500141.html", "external_url": "https://finance.yahoo.com/healthcare/articles/akeso-advances-io2-0-adc2-040500141.html", "title": "Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer", "content_text": "HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) (\"Akeso\" or the \"Company\") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), in combination with ivonescimab (the Company's PD-1/VEGF bispecific antibody), for the treatment of advanced breast cancer. This study aims to explore the potential of Akeso's \"IO2.0 + ADC2.0\" regimen in advanced breast cancer, with a particular focus on first-line treatment of HR+/HER2- breast cancer and triple-negative breast cancer (TNBC). Breast cancer is the second most common malignancy worldwide, with approximately 2.3 million new cases diagnosed annually. Advances in molecular subtype-guided precision medicine\u2014including targeted therapies, immunotherapies, and ADCs\u2014have improved outcomes for patients with certain subtypes. Nevertheless, substantial opportunities remain to enhance both efficacy and safety. Persistent challenges such as resistance in later-line settings, limited availability of effective agents, and marked tumor heterogeneity continue to create significant and urgent unmet clinical needs. These include the limited efficacy of immuno-oncology approaches in PD-L1-negative patients and in those who develop resistance to anti-PD-1 therapy, as well as the safety constraints of ADCs that restrict both therapeutic benefit and the number of treatment lines that can be administered. Exploring novel targets, optimizing combination strategies, and identifying predictive biomarkers for efficacy and resistance remain critical priorities in breast cancer research. Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, has shown strong clinical results compared to PD-1 inhibitor-based therapies across multiple Phase III studies. AK146D1 is a next-generation ADC candidate that has demonstrated potent antitumor activity and a favorable safety profile in early clinical studies. The combination of AK146D1 and ivonescimab has the potential to improve clinical efficacy while maintaining a manageable safety profile, potentially expanding treatment options for patients with advanced breast cancer. Guided by its IO2.0 + ADC2.0 strategy, Akeso is driving the continuous evolution of treatment paradigms for major malignancies such as non-small cell lung cancer and breast cancer. In the immuno-oncology field, Akeso has two approved bispecific antibodies for cancer treatment. The Company is actively evaluating ivonescimab and cadonilimab in combination with its proprietary next-generation ADC candidates. Increasingly, global partners recognize both ivonescimab and cadonilimab as preferred agents for combination regimens and breakthrough therapy explorations across a wide spectrum of tumor types. Story Continues In the ADC space, Akeso has built a differentiated pipeline of next-generation candidates, including AK146D1, AK138D1, AK157D1, and AK158D1 (a bispecific ADC), which are currently in clinical development. These agents are designed to address the narrow therapeutic window and safety limitations commonly associated with first-generation ADCs. Building on the encouraging Phase II clinical data of ivonescimab in breast cancer, a Phase III study evaluating an ivonescimab-based combination as first-line treatment for TNBC is currently underway. In addition to AK146D1, Akeso is also conducting a Phase Ib/II study of its next-generation HER3 ADC (AK138D1) in combination with ivonescimab. Akeso's IO2.0 + ADC2.0 strategy utilizes multi-target and multi-mechanism combinations to harness the synergistic advantages of its pipeline assets. The Company is building a broad portfolio of combination therapies across multiple subtypes and treatment lines in major cancers. This approach seeks to improve clinical outcomes, address resistance challenges, and provide more effective treatment options for patients with advanced breast cancer. Looking ahea", "date_published": "2026-08-10T04:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "9926"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "9926", "name": "Akeso, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/cfc96b07-c8a4-4446-a224-5b867f724c6a/"}]}}, {"id": "source:b0b9e90ccaad350bf8746a28bb646889702db6a1702d6d72551abd8040db76d6", "url": "https://finance.yahoo.com/healthcare/articles/zai-lab-zlab-rising-loss-020846447.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zai-lab-zlab-rising-loss-020846447.html", "title": "Is Zai Lab\u2019s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?", "content_text": "Zai Lab Limited reported second-quarter 2026 results showing revenue of US$106.31 million versus US$109.98 million a year earlier, with net loss widening to US$50.83 million from US$40.73 million and basic loss per share increasing to US$0.50 from US$0.40. Over the first half of 2026, revenue slipped to US$205.92 million while net loss deepened to US$101.84 million, suggesting higher costs or investment needs are weighing more heavily on the income statement than a year ago. We will now examine how this combination of slightly lower revenue and a wider loss affects Zai Lab's previously optimistic investment narrative. Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. Zai Lab Investment Narrative Recap To own Zai Lab today, you need to believe its China focused, in licensed oncology and immunology portfolio can eventually scale enough to cover persistent R&D and royalty costs. The latest results, with slightly softer revenue and a deeper net loss, keep the spotlight on the short term catalyst of new product launches and label expansions, while reinforcing the biggest near term risk that high operating expenses and partnership driven economics could drag out the path to sustainable profitability. Against that backdrop, the recent NMPA approval of TIVDAK in China for recurrent or metastatic cervical cancer stands out. It adds another commercial oncology asset that could support revenue diversification, which looks incrementally more important after a half year of declining sales and wider losses. How quickly TIVDAK is reimbursed and adopted will be an early test of whether Zai Lab's growing pipeline can offset rising costs and competitive pressure in its core markets. Yet, beneath the growth story, investors should also be aware of the risk that sustained high R&D and SG&A spend, combined with heavy reliance on in licensed assets, could... Read the full narrative on Zai Lab (it's free!) Zai Lab's narrative projects $832.0 million revenue and $157.9 million earnings by 2029. Uncover how Zai Lab's forecasts yield a $33.30 fair value, a 43% upside to its current price. Exploring Other PerspectivesZLAB 1-Year Stock Price Chart Some of the most cautious analysts were already assuming only about 16% annual revenue growth and no profits within three years, so this weaker quarter may push their already pessimistic timelines and regulatory risk concerns even further, reminding you that reasonable people can look at the same US$205.92 million half year revenue and US$101.84 million loss and reach very different conclusions. Story Continues Explore 4 other fair value estimates on Zai Lab - why the stock might be worth just $24.25! Reach Your Own Conclusion Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts. A great starting point for your Zai Lab research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Our free Zai Lab research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zai Lab's overall financial health at a glance. Searching For A Fresh Perspective? Opportunities like this don't last. These are today's most promising picks. Check them out now: The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution. This article by Simply Wall", "date_published": "2026-08-10T02:08:46+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "9688"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "9688", "name": "Zai Lab Limited", "sentiment_url": "https://sharemaestro.com/sentiment/6f0d5f29-758a-4179-96ee-db688e92bca8/"}]}}, {"id": "source:3ae80539266fb653a1867b8a8b1ba232dd7953ec0ac6965e206284135c445747", "url": "https://finance.yahoo.com/healthcare/articles/innovent-biologics-daiichi-sankyo-enter-000000414.html", "external_url": "https://finance.yahoo.com/healthcare/articles/innovent-biologics-daiichi-sankyo-enter-000000414.html", "title": "Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA\u00ae Commercialization in China", "content_text": "Collaboration to accelerate access to Vanflyta\u00ae for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta\u00ae (quizartinib) in China. Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta\u00ae while Innovent Biologics holds sole commercialization rights for Vanflyta\u00ae in China, leading market promotion. VANFLYTA was approved in China in June 2026 for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive as detected by an adequate validated diagnostic test, based on the results from the QuANTUM-First trial1. \"This collaboration with Daiichi Sankyo represents an exciting milestone for our hematology franchise. Innovent has continued to expand its product footprint in this field, building a diversified portfolio and strong market presence including TYVYT\u00ae (sintilimab injection), HALPRYZA\u00ae (rituximab injection), olverembatinib, FUCASO\u00ae (Equecabtagene Autoleucel Injection), Jaypirca\u00ae (pirtobrutinib), and the addition of VANFLYTA\u00ae will further enhance our synergistic offerings,\" said Vivian Zhang, Executive Director, Chief Commercial Officer, Innovent Biologics. \"Vanflyta\u00ae (quizartinib) will be the 20th product in Innovent's commercialized product portfolio. Through collaborative efforts, we aim to bring forward innovative medicines to benefit patients with cancer and further strengthen our leadership in oncology.\" \"The partnership with Innovent Biologics reflects our commitment to delivering innovation to patients in China,\" said Michio Hayashi, China President, Daiichi Sankyo. \"By combining our research and development capabilities with Innovent's commercial capabilities in China, we believe this collaboration can accelerate access to VANFLYTA\u00ae for patients with newly diagnosed FLT3-ITD-positive AML and ultimately help improve outcomes in this high-risk patient population.\" About FLT3-ITD Positive Acute Myeloid Leukemia More than 487,000 new cases of leukemia were reported globally in 2022, with more than 305,000 deaths.2 AML accounts for 23.1% of total leukemia cases worldwide and is most common in adults.3,4 In China, nearly 82,000 people were diagnosed with leukemia in 2022 and more than 50,000 people died from the disease, making it the tenth deadliest cancer.5 AML is a common and aggressive subtype, accounting for approximately 50% of leukemia cases in China.6 Story Continues A number of gene mutations have been identified in AML and FLT3 (FMS-like tyrosine kinase 3) mutations are the most common.7 Approximately 80% of FLT3 mutations are FLT3-ITD mutations, which drive cancer growth and contribute to particularly unfavorable prognosis, including increased risk of relapse and shorter overall survival. 7,8 FLT3-ITD mutations occur in about 25% of all AML cases.9 About Vanflyta Vanflyta (quizartinib) is an oral, highly potent type II FLT3 inhibitor that targets FLT3-ITD mutations. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under NMPA review, 5 assets in phase 3 or pivotal clinical trials, and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including ", "date_published": "2026-08-10T00:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "1801"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1801", "name": "Innovent Biologics, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ea41eaf0-aab0-4a09-b5a9-572aceec438c/"}]}}, {"id": "source:a2b053571b6b708146b98a722449e0c2de98cac930c9ce6171f8165665b96dde", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Shanghai Henlius Biotech (SEHK:2696) Advances Oncology Pipeline, Is It Still 64% Below Fair Value?", "content_text": "Shanghai Henlius Biotech (SEHK:2696) Advances Oncology Pipeline, Is It Still 64% Below Fair Value?", "date_published": "2026-08-09T23:31:05+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "2696"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2696", "name": "Shanghai Henlius Biotech, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/55c7d89c-da8d-4227-a98a-95538f48f917/"}]}}, {"id": "source:52d0020cf2568a6e860160e189afdf35a3d7a13bb4ed45662434dcb029ee3d9a", "url": "https://finance.yahoo.com/markets/stocks/articles/zai-lab-zlab-rebounds-following-170920178.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zai-lab-zlab-rebounds-following-170920178.html", "title": "Zai Lab (ZLAB) Rebounds Following Earnings While Its Undervalued Narrative Faces A Fresh Test", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Zai Lab (ZLAB) stock is in focus after the company reported second quarter 2026 results, including revenue of US$106.31 million and a net loss of US$50.83 million, with wider losses than a year earlier. See our latest analysis for Zai Lab. The earnings release seems to have shifted sentiment toward Zai Lab in the short term, with an 11.69% 1 day share price return and a 27.64% 7 day share price return. However, the 1 year total shareholder return is still down 33.30%, which points to short term momentum against a weaker long term record. If this kind of rapid move has you looking beyond a single stock, it could be a good moment to see what else is setting up in AI focused healthcare using the 43 healthcare AI stocks. Given Zai Lab's sharp recent rebound alongside ongoing losses, some investors see a turnaround in progress while others view the move as fragile. Which case lines up better with what the current valuation suggests should happen next? Most Popular Narrative: 30% Undervalued With Zai Lab last closing at $23.32 against a most followed fair value estimate of $33.30, the current price sits well below that narrative view of worth. Multiple high-potential product launches and label expansions over the next 12 to 18 months, combined with a deep pipeline in oncology and immunology, are expected to significantly increase Zai Lab's addressable market and diversify revenue streams, supporting both top-line growth and future earnings. Read the complete narrative. Want to understand why this narrative backs a higher value for Zai Lab? The story leans heavily on fast building revenue, rising margins, and a richer earnings profile. Curious which specific growth path and profitability shift underpin that fair value gap? The full narrative lays out the financial roadmap behind this valuation call. Result: Fair Value of $33.30 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Zai Lab still faces meaningful risks, including competition in China that could pressure future revenue, as well as ongoing high R&D spending that may delay lasting profitability. Find out about the key risks to this Zai Lab narrative. Another View on Zai Lab's Valuation The first narrative leans on a fair value of $33.30 for Zai Lab based on future earnings assumptions. Yet the SWS DCF model points to a future cash flow value of $91.16, which indicates the stock is trading well below that estimate. Which lens do you trust more when the gap is this wide? Story Continues Look into how the SWS DCF model arrives at its fair value.ZLAB Discounted Cash Flow as at Aug 2026 Next Steps Unsure which side of the Zai Lab story feels more convincing right now? Take a closer look at both the risks and potential rewards so you can weigh the 3 key rewards and 1 important warning sign Looking for more investment ideas beyond Zai Lab? If Zai Lab has your attention, do not stop there. Broaden your watchlist now so you are not relying on a single story when new opportunities appear. Target resilient cash generators by scanning companies with the solid balance sheet and fundamentals stocks screener (48 results). Hunt for potential mispricings by reviewing the 52 high quality undervalued stocks before prices move away from you. Spot possible under the radar opportunities early by checking the screener containing 21 high quality undiscovered gems. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamen", "date_published": "2026-08-09T17:09:20+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "9688"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "9688", "name": "Zai Lab Limited", "sentiment_url": "https://sharemaestro.com/sentiment/6f0d5f29-758a-4179-96ee-db688e92bca8/"}]}}, {"id": "source:7cf01fe820756aae8ee01592f93c2c0be101e31ebb3cf0b09061f5ddb132993a", "url": "https://news.google.com/rss/articles/CBMiYEFVX3lxTE8tXzAxR2hnRzZrb1dvSlhHR1NmSDZoYTF3NWlDZEdPekRab2Y1ZFN4MFBBMUlSazZ4SGthNXNINVNvdzN2bURXZjMyUjg1djZlYXdfeDlVNXR0cEpvWDhCMw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiYEFVX3lxTE8tXzAxR2hnRzZrb1dvSlhHR1NmSDZoYTF3NWlDZEdPekRab2Y1ZFN4MFBBMUlSazZ4SGthNXNINVNvdzN2bURXZjMyUjg1djZlYXdfeDlVNXR0cEpvWDhCMw?oc=5", "title": "ETFs Investing in Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Stocks", "content_text": "ETFs Investing in Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Stocks", "date_published": "2026-08-09T02:16:27+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "2591"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2591", "name": "Guangzhou Innogen Pharmaceutical Group Co., Ltd", "sentiment_url": "https://sharemaestro.com/sentiment/b2e7b5de-50d1-40ae-9dba-193877077f7a/"}]}}, {"id": "source:81e742a607926f7b5eb8e282008b340573d713e555b338dada50b74cd9d49e0b", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQdm4tNm5ITndjMTBwOG5yeW9wMWhydE55WUVuVXBNZmpFX1R6MzF2X1NGd19fdnc3RGZBT3MxV1RpdjlFMGFVTWVWazlIQldwQndYOEd5U2taaU5SZnJrb21kUFVfTlRPdDFpQl9jTHh3QXpBVUNvdlR0RlMycXR3WHJrUWZCTGJub0NHSmVYNTQya1FaTlJ4RTZEU0ZjalRjWWVtcVBCVG5hV3RET01CTkRXUGs2aTVnTlFLa2hn?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQdm4tNm5ITndjMTBwOG5yeW9wMWhydE55WUVuVXBNZmpFX1R6MzF2X1NGd19fdnc3RGZBT3MxV1RpdjlFMGFVTWVWazlIQldwQndYOEd5U2taaU5SZnJrb21kUFVfTlRPdDFpQl9jTHh3QXpBVUNvdlR0RlMycXR3WHJrUWZCTGJub0NHSmVYNTQya1FaTlJ4RTZEU0ZjalRjWWVtcVBCVG5hV3RET01CTkRXUGs2aTVnTlFLa2hn?oc=5", "title": "Qyuns Therapeutics Sets Board Meeting to Approve 2026 Interim Results", "content_text": "Qyuns Therapeutics Sets Board Meeting to Approve 2026 Interim Results", "date_published": "2026-08-07T12:50:34+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "2509"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2509", "name": "Qyuns Therapeutics Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/0caa9df0-fa80-47bf-ae3e-157fdb86a9f4/"}]}}, {"id": "source:afe1e40b04ee222e71f6345ced6167894315ec8f370188da46502fbd813bd586", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQUGpPbUJvcGVSQUV2ZGJzR2kzVnBia1ZaTzJnV1JGTWU0WTAtZjhWeTFYZFRsWWpMYUs3YWpFOW9ZNUpxQzFOMl9IbnFUMVFaREc2UXVlVGlSUVhEOTR3ZVJOOGxKVUJyeUI3bmVLVENUYWZNYm5pN0s4LW9uNGh6dnB1V1RmNG42NF81ZGJtRnduSl91aFphY01Eb0RoVWxUTEN2alhfSFAzaC1ieFAyNW5kOGU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQUGpPbUJvcGVSQUV2ZGJzR2kzVnBia1ZaTzJnV1JGTWU0WTAtZjhWeTFYZFRsWWpMYUs3YWpFOW9ZNUpxQzFOMl9IbnFUMVFaREc2UXVlVGlSUVhEOTR3ZVJOOGxKVUJyeUI3bmVLVENUYWZNYm5pN0s4LW9uNGh6dnB1V1RmNG42NF81ZGJtRnduSl91aFphY01Eb0RoVWxUTEN2alhfSFAzaC1ieFAyNW5kOGU?oc=5", "title": "Laekna Schedules Board Meeting to Approve 2026 Interim Results", "content_text": "Laekna Schedules Board Meeting to Approve 2026 Interim Results", "date_published": "2026-08-07T12:20:13+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "2105"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2105", "name": "Laekna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/c92adecf-11a6-44c0-9de2-de6c2b560f07/"}]}}, {"id": "source:49b73aa734e9e596040cc72b47acbc4e25468a1b91daf991861789d9584ae6d3", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNSFRuWDJWMjFGUGhKM3A3VjMwa05oa3ZtN2J3N3dmTl9DUlN5NWJaSDFxODUwcUdRNUFEM0JIOEs3TFJCRTF2d3VqRE5uYlBJVml2NHZ3MnhlU0hZRW5vQWNldTRsQUwyN1F1YU5ZOGtLNGlMamJjdzlFRUlFX1hUWjVSbDNDUEJzNlJyYXdObks0MnRjVkNrbWViVlBqTy1LMkhNZ2sxUUJZUktoYXJmeUs4Mk9Ta3JWcjR0T1FQTQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNSFRuWDJWMjFGUGhKM3A3VjMwa05oa3ZtN2J3N3dmTl9DUlN5NWJaSDFxODUwcUdRNUFEM0JIOEs3TFJCRTF2d3VqRE5uYlBJVml2NHZ3MnhlU0hZRW5vQWNldTRsQUwyN1F1YU5ZOGtLNGlMamJjdzlFRUlFX1hUWjVSbDNDUEJzNlJyYXdObks0MnRjVkNrbWViVlBqTy1LMkhNZ2sxUUJZUktoYXJmeUs4Mk9Ta3JWcjR0T1FQTQ?oc=5", "title": "Nanjing Leads Biolabs Advances Key Liver Cancer Trial for Opamtistomig", "content_text": "Nanjing Leads Biolabs Advances Key Liver Cancer Trial for Opamtistomig", "date_published": "2026-08-06T09:52:49+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "9887"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "9887", "name": "Nanjing Leads Biolabs Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/2c748e50-3024-40af-bd16-ef3f34d58d79/"}]}}, {"id": "source:2395ac1eba2fb2d9d3f226b1e1418e7e2a3a8c27e29dee4ba5bad90908450200", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUGFoNTFEdTBENzhzZGFlbVJxM0l0UmN4M3p3a3ZqdDJYRE1GWFFXODVlNXU1T1BOYlVOMUp6eTJralhKV0F1a3NwTC1xVV9BVHB4R0ZwSU5QTGFMUnZZaVRNZjhldjVPZVU0TEN5MXZEQTJhY2VqSmtaV01BTTNZNi1JcjdvcDc1c1dienUySjVzTXFMQTFfMEE4VmxjajJjNlVPSnViX1JEdw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUGFoNTFEdTBENzhzZGFlbVJxM0l0UmN4M3p3a3ZqdDJYRE1GWFFXODVlNXU1T1BOYlVOMUp6eTJralhKV0F1a3NwTC1xVV9BVHB4R0ZwSU5QTGFMUnZZaVRNZjhldjVPZVU0TEN5MXZEQTJhY2VqSmtaV01BTTNZNi1JcjdvcDc1c1dienUySjVzTXFMQTFfMEE4VmxjajJjNlVPSnViX1JEdw?oc=5", "title": "Enterprise value to revenue forward of Cutia Therapeutics \u2013 HKEX:2487", "content_text": "Enterprise value to revenue forward of Cutia Therapeutics \u2013 HKEX:2487", "date_published": "2026-08-05T07:11:09+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "2487"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2487", "name": "Cutia Therapeutics", "sentiment_url": "https://sharemaestro.com/sentiment/c16d05c0-7950-490a-b83a-895e50b4f8af/"}]}}, {"id": "source:cac362fcd213138f1f5e5760c16cfb80c24111bb8415e26c6d84b3f1cce725ad", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNbWtKNEhRRE5YS3FqOHY3UUJzc2JEOEp6NXd1aUNySm5yY3VPdDU1V0pEVnVrV3lMc0JETGozbU5VLXpGVkNvYzlfQTBvdG5ma0NsZU42eE9CY3VGeW5CV19Ldkd2ZVN2RHd4dlZRTFlEekN0eHhUNVZkbEpYalpxOGhXTnFybGFtSE55TEZwZFl1bGZHRVVELVlKYlhOZ3dwY2hFM21YMUNFQTd5NVNvMXdIUXBDNjI1cFhyWVhXY05xejktbmJtTGNR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNbWtKNEhRRE5YS3FqOHY3UUJzc2JEOEp6NXd1aUNySm5yY3VPdDU1V0pEVnVrV3lMc0JETGozbU5VLXpGVkNvYzlfQTBvdG5ma0NsZU42eE9CY3VGeW5CV19Ldkd2ZVN2RHd4dlZRTFlEekN0eHhUNVZkbEpYalpxOGhXTnFybGFtSE55TEZwZFl1bGZHRVVELVlKYlhOZ3dwY2hFM21YMUNFQTd5NVNvMXdIUXBDNjI1cFhyWVhXY05xejktbmJtTGNR?oc=5", "title": "3D Medicines Inc. Announces Change Of Principal Place Of Business In Hong Kong", "content_text": "3D Medicines Inc. Announces Change Of Principal Place Of Business In Hong Kong", "date_published": "2026-08-04T14:10:00+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Market update", "1244"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1244", "name": "3D Medicines Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/008d0abc-4812-4c33-8b50-00720dfd274b/"}]}}, {"id": "source:7b853a536b77595bf958d77132f0877abd22c8935e5b04401702028f255ba8d5", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPLXlWbG1VaDZtRHQwaXVDSnp1anJJSE94RF93RVQ2S1E5TFRSamZKS18xSGJfY0VReFpMdnI4RU42dFF4YzZ0NmkyNGEyUEdwMzlROXZrQ3BTUmMyU2RNSUNyUkxzWmoyUmJNd25BZHpMMmQxSks4UTE0ZHM4cm4xQTFfWW1OTVppZGYyallSWmhxQU1ZR29za29PbGhrNl92b0FzODVSYWhFUEhKQ0Z0VU5OR0tQSHE0TWNzRW9wVzhTblZGbkJocnRCRXBWNkN4clUzTWZ1X1JOMU5ldEdDZzhSUUM?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPLXlWbG1VaDZtRHQwaXVDSnp1anJJSE94RF93RVQ2S1E5TFRSamZKS18xSGJfY0VReFpMdnI4RU42dFF4YzZ0NmkyNGEyUEdwMzlROXZrQ3BTUmMyU2RNSUNyUkxzWmoyUmJNd25BZHpMMmQxSks4UTE0ZHM4cm4xQTFfWW1OTVppZGYyallSWmhxQU1ZR29za29PbGhrNl92b0FzODVSYWhFUEhKQ0Z0VU5OR0tQSHE0TWNzRW9wVzhTblZGbkJocnRCRXBWNkN4clUzTWZ1X1JOMU5ldEdDZzhSUUM?oc=5", "title": "Nanjing Leads Biolabs Advances Autoimmune Drug LBL-051 Into First-in-Human Trial", "content_text": "Nanjing Leads Biolabs Advances Autoimmune Drug LBL-051 Into First-in-Human Trial", "date_published": "2026-08-04T07:00:00+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "9887"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "9887", "name": "Nanjing Leads Biolabs Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/2c748e50-3024-40af-bd16-ef3f34d58d79/"}]}}, {"id": "source:36c718e687c9b704467549b6d81f624246463e43338f8c761044fccdfc745a66", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPRmM4eXVsQXZoVmo0eWI4Zlh6NldCQmtYZmNNOGJodTNobDhwYU9aRXZEOEdNV18zeDB6N2JUb2hGM09qM0N2X19JTTZvcGRPeE9MZmQ1R01NanQ1eVV5azEtdTBPRHNPakxYUlRXNzYwajVpWWtwV0M2VXRKZm83MHpKZXRBMEh4TVhkaFBxc3B6ODN5ZFlHU0psTFNZazJvOFIyUG5laHZwcHVMLVNOT3B5Q29qV3F0NDZ6bkVtR3pRTE5pSjFyYjIyU2kxVmx4?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPRmM4eXVsQXZoVmo0eWI4Zlh6NldCQmtYZmNNOGJodTNobDhwYU9aRXZEOEdNV18zeDB6N2JUb2hGM09qM0N2X19JTTZvcGRPeE9MZmQ1R01NanQ1eVV5azEtdTBPRHNPakxYUlRXNzYwajVpWWtwV0M2VXRKZm83MHpKZXRBMEh4TVhkaFBxc3B6ODN5ZFlHU0psTFNZazJvOFIyUG5laHZwcHVMLVNOT3B5Q29qV3F0NDZ6bkVtR3pRTE5pSjFyYjIyU2kxVmx4?oc=5", "title": "Ascletis Pharma Schedules Board Meeting to Review 2026 Interim Results and Dividend", "content_text": "Ascletis Pharma Schedules Board Meeting to Review 2026 Interim Results and Dividend", "date_published": "2026-08-03T18:38:20+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "1672"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1672", "name": "Ascletis Pharma Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/c3d1ab5c-d74a-49c7-a7f9-380f2167dfd4/"}]}}, {"id": "source:90939f98f4519bf8449ed8d261f081a5c26f73d2907ce983276492563e496df4", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNSEJMRWljSG9UaDRPZTgtZDB6VEVfdzRZUjFtWE5PSHF0eUx6RzhYamVBUzFXSHkyV08zOG9BRmhicTdhbk1MRFJYdU93SzkzdXhibGRpRW1Bb1ZVZFQwSUMzQkp3R0FSUUtiallSbFJ2QkM3ZkdxNTdkYnp5aDdJSlZVYXVVakRuVG50SlZ3WFFoSXRZSTFQbFNFbHloUGtCXzlMY2RvX2t4WV94NGgtR2dYYlRTWW5kSlFWN252d1VpTFVJRDIwX05qZUk?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNSEJMRWljSG9UaDRPZTgtZDB6VEVfdzRZUjFtWE5PSHF0eUx6RzhYamVBUzFXSHkyV08zOG9BRmhicTdhbk1MRFJYdU93SzkzdXhibGRpRW1Bb1ZVZFQwSUMzQkp3R0FSUUtiallSbFJ2QkM3ZkdxNTdkYnp5aDdJSlZVYXVVakRuVG50SlZ3WFFoSXRZSTFQbFNFbHloUGtCXzlMY2RvX2t4WV94NGgtR2dYYlRTWW5kSlFWN252d1VpTFVJRDIwX05qZUk?oc=5", "title": "Guangzhou Innogen Gains PIC/S GMP Approval for Efsubaglutide Manufacturing Sites", "content_text": "Guangzhou Innogen Gains PIC/S GMP Approval for Efsubaglutide Manufacturing Sites", "date_published": "2026-08-03T12:29:57+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Regulatory and legal", "2591"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2591", "name": "Guangzhou Innogen Pharmaceutical Group Co., Ltd", "sentiment_url": "https://sharemaestro.com/sentiment/b2e7b5de-50d1-40ae-9dba-193877077f7a/"}]}}, {"id": "source:c5886c92e37e180e3bbf7aefed436e8729bfd70535b5a8b2594dcae2854931c2", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNUTJMRWwtb1VrMFdkTjUxLUQtbkF6aFJVVVE5c0EtbHZQRFZ3cHpZR2F4ZF9Tbk9HTTc2bzdZWnpUekxXelpZM2Z2N19WTXJFQkdtU1Y0dXd4akFKMEV3dzZmc0c0ckVJUm9ramVDSlI4ZkdsWnpEQ09ETDNHZGFSVlRxVGhCWTA3VjY5YkM4UGV1RU9mRHp6akM1RGtwN21heXhUNGF0d2x0eTQwcGVPa0ExMV8wUlQ2ODIybkowZEhxTDJIalFNSzF1QTRUeGtfRERuRWFIRnl3UGg4MUZNY2EzOG9wUXpo0gHuAUFVX3lxTE1qTkNiSFNxOTBNMVNlbVRUTkktMXJKOWdVdEY2YktSNjBkMXFidFhfNklOLWVucjhodHo2RTljV3pEN1VqTDRMSjVQVml4ZnZSYnBabU5XbngyV1kxeFo1QTFCRkpraXN4LV9Lc3ZvS2RkMzJRRWVVUE1iT2syMkktMjh1cHJ3WDFxWHM0eHNTQzZHSmN2TFFiMUIyVmtyS1Z2UVRQV2NxeFNzWmpPOEVjMVpabDBfalJWV2dZMkRHbE5WV3NWRTFlMVVSRHR1TDc3ZEJZMFNwRmMzQjVHbG5IOHBGU1M5aTY1czdmZXc?oc=5", "title": "Is Ascletis\u2019 Biologic Obesity Pipeline Altering The Investment Case For Ascletis Pharma (SEHK:1672)?", "content_text": "Is Ascletis\u2019 Biologic Obesity Pipeline Altering The Investment Case For Ascletis Pharma (SEHK:1672)?", "date_published": "2026-08-03T07:00:00+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "1672"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1672", "name": "Ascletis Pharma Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/c3d1ab5c-d74a-49c7-a7f9-380f2167dfd4/"}]}}, {"id": "source:7414ea39d27ef0bc8b4ab242419a5690dda9a78f5089ccafd7be692a77bae873", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQbHIxQ29Zc1UzRlBrdE96YjRGZDNEYmFVWlB6RDZHNnFzN3RHQUxnYnFVQWtYYjVYUmhxQXF5UnlBakxQYnhTdUF6ZmRyT0xsSG55UzkwZk9jQ0xOQzEwTXd4MVRTTExKMDdUdlM2S1FoaEtrZTZsZ3h2RnR2YkxOLU9TOUxlUzkxWEoxYnkxTzd3NHlLSU9fMDB4Y3dvcFVPU0lOX183aTJZU0xwQWZvVXIxeVRnWUxPUEJxNHdpT0l1UGcxYUY3UkRqbTJFWmdQOFFJR2c5d05FUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQbHIxQ29Zc1UzRlBrdE96YjRGZDNEYmFVWlB6RDZHNnFzN3RHQUxnYnFVQWtYYjVYUmhxQXF5UnlBakxQYnhTdUF6ZmRyT0xsSG55UzkwZk9jQ0xOQzEwTXd4MVRTTExKMDdUdlM2S1FoaEtrZTZsZ3h2RnR2YkxOLU9TOUxlUzkxWEoxYnkxTzd3NHlLSU9fMDB4Y3dvcFVPU0lOX183aTJZU0xwQWZvVXIxeVRnWUxPUEJxNHdpT0l1UGcxYUY3UkRqbTJFWmdQOFFJR2c5d05FUQ?oc=5", "title": "Nanjing Leads Biolabs Wins IND Nod for Bispecific Antibody in Metastatic Colorectal Cancer", "content_text": "Nanjing Leads Biolabs Wins IND Nod for Bispecific Antibody in Metastatic Colorectal Cancer", "date_published": "2026-08-02T22:58:28+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "9887"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "9887", "name": "Nanjing Leads Biolabs Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/2c748e50-3024-40af-bd16-ef3f34d58d79/"}]}}, {"id": "source:cb764b56e0a09b8853678ae8eb27a37876663545f744aeebfdcdbd48d608ecfb", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Nanjing Leads Biolabs Completes Phase II Enrollment for Opamtistomig in Biliary Tract Cancer", "content_text": "Nanjing Leads Biolabs Completes Phase II Enrollment for Opamtistomig in Biliary Tract Cancer", "date_published": "2026-08-01T19:18:53.670656+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "9887"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "9887", "name": "Nanjing Leads Biolabs Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/2c748e50-3024-40af-bd16-ef3f34d58d79/"}]}}, {"id": "source:67e44f9b6f75f8dab7def1c0ffa436bfea893a00b7295ff58f3a4f9f61a041cc", "url": "https://news.google.com/rss/articles/CBMidEFVX3lxTE9UWEl0Y2VPVnB4VkVSekloNGd2cjRvMk5WdEIyaWcwTWpHNzRxa1d1b0E5dXRhYVFsMzQzaGw3YUlnVF83RU9faFVfa0JiZWpvRFRpUWFtTW5pRFZaLTE2MjJOb2E1M2xRZDNfSWc3QVJISncz?oc=5", "external_url": "https://news.google.com/rss/articles/CBMidEFVX3lxTE9UWEl0Y2VPVnB4VkVSekloNGd2cjRvMk5WdEIyaWcwTWpHNzRxa1d1b0E5dXRhYVFsMzQzaGw3YUlnVF83RU9faFVfa0JiZWpvRFRpUWFtTW5pRFZaLTE2MjJOb2E1M2xRZDNfSWc3QVJISncz?oc=5", "title": "3SBio, Inc. Revenue Breakdown \u2013 HKEX:1530", "content_text": "3SBio, Inc. Revenue Breakdown \u2013 HKEX:1530", "date_published": "2026-08-01T06:12:31+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "1530"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1530", "name": "3SBio Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d75b4106-c7a2-4ecb-868f-eae659219553/"}]}}, {"id": "source:6c7874953a14247c21e99fa18ccde2607f6ba7bb8fdce0c425fcd4da3ca206f3", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQZ3JFaDYzZF9MLU11dTJrZUQtX3pZWVVFLUhQb1Q1OERQb0FyTFZXYVFub3R6YmF0WWNxSDlSVk42TlRLSjVkeDBJS2t3VWJ1Uy1adEdLeVF3MS14d1NsLU85YU9rQk1JSEMwX1czQ0ZqQWhUaEFVRjJrcENybVhMUFJkeHVWZUNpWWh3N1lhUVdGV3FTcnhlUFI3U2xsU1BZTHBZcTdsYi1mVEFLNkNzREt6QzVaMTAyczJpcHRmQXhVMTBEY1VRRzNSYVZZYWduaUppR2Q3Z1UxbjFqaDdZOXpwR1FqZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQZ3JFaDYzZF9MLU11dTJrZUQtX3pZWVVFLUhQb1Q1OERQb0FyTFZXYVFub3R6YmF0WWNxSDlSVk42TlRLSjVkeDBJS2t3VWJ1Uy1adEdLeVF3MS14d1NsLU85YU9rQk1JSEMwX1czQ0ZqQWhUaEFVRjJrcENybVhMUFJkeHVWZUNpWWh3N1lhUVdGV3FTcnhlUFI3U2xsU1BZTHBZcTdsYi1mVEFLNkNzREt6QzVaMTAyczJpcHRmQXhVMTBEY1VRRzNSYVZZYWduaUppR2Q3Z1UxbjFqaDdZOXpwR1FqZw?oc=5", "title": "Shanghai Henlius Biotech, Inc. Announces Approval of Investigational New Drug Application for Clinical Trial of HLX43 for Injection in Combination with Bevacizumab for Treatment of Advanced or Metastatic Solid Tumours", "content_text": "Shanghai Henlius Biotech, Inc. Announces Approval of Investigational New Drug Application for Clinical Trial of HLX43 for Injection in Combination with Bevacizumab for Treatment of Advanced or Metastatic Solid Tumours", "date_published": "2026-07-31T07:00:00+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Regulatory and legal", "2696"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2696", "name": "Shanghai Henlius Biotech, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/55c7d89c-da8d-4227-a98a-95538f48f917/"}]}}, {"id": "source:ac88f00a61cc726aba80c3c0b3c23b9b36d539e7d9ba70981ed4f6c6ac1d25d5", "url": "https://news.google.com/rss/articles/CBMidEFVX3lxTE5WLVQ1cFhRcnpVUXQwcEdiY3hVd1ZtOE83OHhCblczdjlncllVRGlETlBZQURkbENRT1BuNmNXdHBrNVhNdklFYW5CX09TNDhwdTNzWVVrVzVLMXBuSGNhSHJtNzhlaU4yV0pJTWlNZVJKazlf?oc=5", "external_url": "https://news.google.com/rss/articles/CBMidEFVX3lxTE5WLVQ1cFhRcnpVUXQwcEdiY3hVd1ZtOE83OHhCblczdjlncllVRGlETlBZQURkbENRT1BuNmNXdHBrNVhNdklFYW5CX09TNDhwdTNzWVVrVzVLMXBuSGNhSHJtNzhlaU4yV0pJTWlNZVJKazlf?oc=5", "title": "PegBio Co., Ltd. Class H Revenue Breakdown \u2013 HKEX:2565", "content_text": "PegBio Co., Ltd. Class H Revenue Breakdown \u2013 HKEX:2565", "date_published": "2026-07-28T17:16:30+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "2565"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2565", "name": "PegBio Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/2cbbefa2-8b07-4f6f-82d4-1d549f519d7b/"}]}}, {"id": "source:9945130b031660320227c4f808c6af30492f5fcfcd27fe5a89f3e8b6beb16fe7", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOcGoyLU55MFdZUDdNU0xKUDJWc1ZiSG84YnhKZTJKZEFzek95Rk1qOXNPaE5pYUhGdTlQX0s2X3NWa0pmZm8ybVI1eHlsZTlVblQ1NjRSMl9rRm12TjZTZjlZOFZMVkhMRHV6djdPajgzSXZnVTljM0stQmozNnh3UTVzNVVKbmlyNGc5R29TelNiVURSTUt6TnBBUVR2SVJ0R2Z5U0k2ZXJfMndYT2s5bjlrNA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOcGoyLU55MFdZUDdNU0xKUDJWc1ZiSG84YnhKZTJKZEFzek95Rk1qOXNPaE5pYUhGdTlQX0s2X3NWa0pmZm8ybVI1eHlsZTlVblQ1NjRSMl9rRm12TjZTZjlZOFZMVkhMRHV6djdPajgzSXZnVTljM0stQmozNnh3UTVzNVVKbmlyNGc5R29TelNiVURSTUt6TnBBUVR2SVJ0R2Z5U0k2ZXJfMndYT2s5bjlrNA?oc=5", "title": "Antengene Results Supported by Income From Licensing Agreements >6996.HK", "content_text": "Antengene Results Supported by Income From Licensing Agreements >6996.HK", "date_published": "2026-07-27T07:00:00+00:00", "authors": [{"name": "moomoo.com"}], "tags": ["Earnings", "6996"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "6996", "name": "Antengene Corporation Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3a953705-10d5-42ca-92f3-2c3c0dcfa50a/"}]}}, {"id": "source:30a86917f4282aa0045d899ecf22f7b35fa5e5612d3cfc45fa84c93491c9990c", "url": "https://news.google.com/rss/articles/CBMidEFVX3lxTE1NVDVObDA5N1p4c1Z0M1lnOHh5blZDV1JBcjF0Njhla09Sbm1vSGRjWjdjNVItX0pJQXNwcHd5Q20xMVNITlNaenRHaGtGTkVmZXF4YWEyWm9VQl9fYjNEWWhfSTVfRlZMUjFDeDhwdk5wQUN2?oc=5", "external_url": "https://news.google.com/rss/articles/CBMidEFVX3lxTE1NVDVObDA5N1p4c1Z0M1lnOHh5blZDV1JBcjF0Njhla09Sbm1vSGRjWjdjNVItX0pJQXNwcHd5Q20xMVNITlNaenRHaGtGTkVmZXF4YWEyWm9VQl9fYjNEWWhfSTVfRlZMUjFDeDhwdk5wQUN2?oc=5", "title": "Shanghai Henlius Biotech, Inc. Class H Revenue Breakdown \u2013 HKEX:2696", "content_text": "Shanghai Henlius Biotech, Inc. Class H Revenue Breakdown \u2013 HKEX:2696", "date_published": "2026-07-24T17:22:23+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "2696"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2696", "name": "Shanghai Henlius Biotech, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/55c7d89c-da8d-4227-a98a-95538f48f917/"}]}}, {"id": "source:8279fab0be2bc1cdc50f2b7d876a26919b3bb157d39f57ee2be1d17f2f8954dc", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Shanghai Henlius Biotech (SEHK:2696) Advances Pipeline As Fair Value Questions Grow", "content_text": "Shanghai Henlius Biotech (SEHK:2696) Advances Pipeline As Fair Value Questions Grow", "date_published": "2026-07-21T07:00:00+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "2696"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2696", "name": "Shanghai Henlius Biotech, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/55c7d89c-da8d-4227-a98a-95538f48f917/"}]}}]}